Bradley McGregor

FASCO, Assistant Professor Harvard Medical School; Director of Clinical Research, Lank Center for GU Oncology DFCI COI -coi.asco.org/share/EXE-GEFM…

[Bradley McGregor @BradMcG04]

Now enrolling through @ALLIANCE_org - STRIKE! (A032201) exploring the role of Tivozanib with pembrolizumab following resection of ccRCC - check out our TIP at #GU26 @ASCO @DanaFarber_GU https://t.co/ThH1RX9Dkj

[Bradley McGregor @BradMcG04]

@lalaniMD @OncoAlert @Uromigos @AmandaNizamMD @DrKarineTawagi @nataliagandur @ReneeSaliby @NazliDizman @uromigosjapan @TresUramigas @weoncologists @DrChoueiri @montypal @HHammersMD @tompowles1 @brian_rini @DrRanaMcKay @bergsa83 @BraunMDPhD @MosheOrnsteinMD STRIKE! AO32201 - exploring pembro with or without 6 months if pembro in adjuvant setting is open - positive dfs seen with pembro/bel shows combinations can be effective in adjuvant setting

[Uromigos @Uromigos]

Team America 🇺🇸 🇨🇦 have their educational video - with novel soundtrack - for Uromigos cup 🏆. Eurasia is winning. ♥️ =points. Surely it’s time for a win for the Americas. #UromigosLive @OncoAlert @montypal

[Bradley McGregor @BradMcG04]

At @AUC3 2024, everyone agreed - it is time to retire the prognostic tools as predictive biomarkers and focus on biology. Look forward to discussing this and more at $UromigosLive 2025 @Uromigos @OncoAlert
https://t.co/imTCKXoWVC

[Uromigos @Uromigos]

The UromigosLive 2025 meeting presents #UromigosShorts videos on GU Oncology topics. The videos with the most views win a prize at #UromigosLive November 7-8th in Nashville, TN. Below,  Dr. Bradley MCGreggor discusses: Favorable Risk RCC.

[Bradley McGregor @BradMcG04]

Thank you so much for the invitation - was great to meet everyone at City of Hope and see the amazing work being done!

[Sumanta K. Pal, MD, FASCO @montypal]

A stellar @cityofhope Medical Oncology Grand Rounds delivered by @BradMcG04 @DanaFarber. Brilliant overview of #adjuvant tx for #kidneycancer that set the stage for his P3 @ALLIANCE_org trial comparing #pembrolizumab +/- #tivozanib.

[Neelima Denduluri @ndenduluri1]

So grateful for my journey across the oceans and @LSUHS @georgetownmed @NIH @theNCI @TheUSONetwork - thank you @jamecancerdoc @ASCO @ASCOPost

[Bradley McGregor @BradMcG04]

As we decide how to treat a patient with fav risk RCC - why are we using clinical prognostic tools to predict benefit of one therapy over another? @DrChoueiri @montypal @DanaFarber_GU https://t.co/imTCKXoWVC

[Uromigos @Uromigos]

The UromigosLive 2025 meeting presents #UromigosShorts videos on GU Oncology topics. The videos with the most views win a prize at #UromigosLive November 7-8th in Nashville, TN. Below,  Dr. Bradley MCGreggor discusses: Favorable Risk RCC.

[Bradley McGregor @BradMcG04]

Amazing weather for @PanMass this year - over 20 down! Still time
To donate! https://t.co/YB3Z2KPcKe

[Bradley McGregor @BradMcG04]

@crisbergerot @ASCO Starting with tivozanib 1.34 mg D1-21 every 28 days important - in later line setting need to optimize tki dose adjusting as neeed for toxicities to get greatest benefit

[Bradley McGregor @BradMcG04]

It was a great run - join us tomorrow am at 545 in Marriott Marquis lobby for all run along the Embarcadero to finish off #GU25 @ASCO @maughanonc @montypal

[Bradley McGregor @BradMcG04]

Weather looks to be ok! Let’s start day 2 of #GU25 with a run along the Embarcadero - meet in Marriott lobby at 545! @ASCO @maughanonc @montypal @DrChoueiri

[Bradley McGregor @BradMcG04]

STRIKE activated; download docs today! @ALLIANCE_org @theNCI Can we prevent more recurrences with addition of 6 months of Tivozanib to 1 year of pembrolizumab in patients with resected high risk ccRCC? @Daniel_J_George @DrRosenbergMSK @MattGalsky @DrChoueiri

[Bradley McGregor @BradMcG04]

Great way to start final day of #IKCSNA24 with 5 mile run in Louisville with @maughanonc @MichaelPalliola

[Bradley McGregor @BradMcG04]

Great way to end #ESMO2024 with sunrise run along the beach @maughanonc

[Bradley McGregor @BradMcG04]

Thanks @PBarataMD for highlighting CAN-I! Poster up at #ESMO24; with extended followup Cabo/nivo/ipi with ORR 21% in RCC with divergent histologies though significant toxicity. Work ongoing correlating pdl1 and genomics with response @DrChoueiri @VincentWenxinXu @DanaFarber_GU

[Bradley McGregor @BradMcG04]

Up now - DAD update for #ESMO24! With 22 month followup SG+EV for 2L+ active with no new toxicity signals. ORR 70% with 4 CR; 6 patients with ongoing response - median DOR 10 months (range 3-33+). DADIO coming soon! @OncoBellmunt @DrChoueiri @DanaFarber_GU

[Bradley McGregor @BradMcG04]

Beautiful AM for a 5k to start the day at #ESMO2024 @OncoAlert @MichaelPalliola

[Bradley McGregor @BradMcG04]

NKT2152 an oral hf2 inhibitor with half life of 38 days has activity in heavily treated ccRCC with ORR 20% (26% with longer followup) with no unexpected toxicity. Trials ongoing exploring dose and activity following belzutifan - open @DanaFarber_GU @DrChoueiri

[Bradley McGregor @BradMcG04]

Nivo/ipi improves 12 month overall survival rate vs SOC with ORR 33%; responses seen in 7 patients (25% ORR) with chromophobe RCC. PDL1 may be a predictive biomarker #ESMO2024 @DrChoueiri @lalaniMD

[Bradley McGregor @BradMcG04]

First presentation of @myESMO - addition of nivoluamb to tiovzanib does not improve outcomes following progression on immunotherapy; tivozanib with encouraging PFS of over 9 months when used second line - full data in @TheLancet @DrChoueiri @lalaniMD @DanaFarber_GU